Gujarat Kidney & Super Speciality IPO Opens Today; IPO Price Band Set at ₹108.00 to ₹114.00 Per Share 

Mumbai, 22 December 2025: Multispeciality healthcare service provider, Gujarat Kidney & Super Speciality Limited’s IPO has opened today, 22 December 2025. The company intends to raise ₹ 250.80 crore through this IPO, comprising 2.20 crore equity shares of face value of ₹ 10 each under the fresh issue route without any offer for sale (OFS) component. 

The IPO will close on December 24, 2025. The allotment for the Gujarat Kidney IPO is expected to be finalised on December 26, 2025, with the shares listing on BSE, NSE with a tentative listing date fixed as December 30, 2025. 

Incorporated in 2019, Gujarat Kidney and Super Speciality Limited (GKASSL) specialize in providing multispeciality healthcare services, including secondary and tertiary care, across multiple locations in Gujarat, India. The company operates seven multispeciality hospitals and four pharmacies with a total bed capacity of 490 beds, an approved capacity of 455 beds, and an operational capacity of 340 beds. 

Gujarat Kidney & Super Speciality Price Band Set between ₹108.00 and ₹114.00 Per Share; Lot size 128 Shares 

Gujarat Kidney and Super Speciality IPO is a book build issue of ₹250.80 crores. The issue is entirely a fresh issue of 2.20 crore shares of ₹250.80 crore. 

The IPO price band is set at ₹108.00 to ₹114.00 per share. The lot size for an application is 128. The minimum amount of investment required by a retail is ₹14,592 (128 shares) (based on upper price). The lot size investment for sNII is 14 lots (1,792 shares), amounting to ₹2,04,288, and for bNII, it is 69 lots (8,832 shares), amounting to ₹10,06,848. 

Nirbhay Capital Services Pvt.Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue. 

Gujarat Kidney & Super Speciality Utilisation of Proceeds towards Several Strategic Purposes 

The company proposes to utilise the net proceeds from the issue towards proposed acquisition of Parekhs Hospital at Ahmedabad (₹77.00 crore), part payment of purchase consideration for the already acquired “Ashwini Medical Centre” (₹12.40 crore), funding of capital expenditure requirements towards setting up of a new hospital in Vadodara (₹30.10), and buying robotics equipment (₹6.83 crore). 

In addition, the IPO proceeds will also be used to prepay or repay in full or part of certain outstanding secured borrowings (₹1.20 crore), funding the acquisition of additional shareholding in company’s subsidiary, Harmony Medicare Private Limited, at Bharuch (₹10.78 crore), and funding inorganic growth through unidentified acquisitions and general corporate purposes. 

Gujarat Kidney & Super Speciality Ltd Witnesses 637% Revenue Growth and ROCE at 38% 

Gujarat Kidney & Super Speciality Ltd. saw a significant turnaround in its performance from FY24 to FY25. Income from operations increased to ₹40.40 crore in FY25 from ₹5.48 crore in FY24, recording a strong growth of 637%. Profit after tax increased by 454% to ₹9.50 crore from ₹1.71 crore. EBITDA grew substantially to ₹16.55 crore from ₹1.95 crore. The assets grew to ₹55.34 crore and the net worth was robust at ₹25.71 crore due to higher reserves and controlled borrowings. 

In terms of metrics, the company posted strong efficiency and profitability metrics in FY25. Return on equity and return on net worth both stood at 36.61% whereas Return on capital employed was 37.65%. Profitability ratios were strong, with 23.61% PAT margin and 41.12% EBITDA margin. The debt-equity ratio was a modest 0.15, suggesting conservative gearing. The price to book value ratio was 22.62 which shows the market valuation with respect to the net worth. 

Subscription Status of Gujarat Kidney & Super Speciality IPO (10:54 AM) 

As of Day, 22 December, 10:54 AM, Gujarat Kidney IPO was subscribed 0.34 times. The issue witnessed robust response from Retail Investors, as this segment was subscribed 1.52 times, with bids received for 33.52 lakh shares against 22 lakh shares on offer. Non-Institutional Buyers (NIB) subscribed 0.35 times, with bNIIs subscribing 0.38 times and sNIIs subscribing 0.29 times. The QIB portion (excluding anchor investors) remain unsubscribed so far. 

Source: https://www.nseindia.com/market-data/issue-information?symbol=GKSL&series=EQ&type=Active

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.  

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.  

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations